Selected references
- Tamakoshi K, Kikkawa F, Nakashima N, Tamakoshi A, Kawai M, Furuhashi Y, Hattori SE, Kuzuya K, Arii Y, Suganuma N, Tomoda Y. Clinical behavior of borderline ovarian tumors: a study of 150 cases. J Surg Oncol 1997; 64:147–152
- Puls LE, Powell DE, DePriest PD, Gallion HH, Hunter JE, Kryscio RJ, van Nagell JR Jr. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992; 47:53–57
Further reading
- Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005;65:10602–10612
- Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511–1518
- Scott M, McCluggage WG. Current concepts in ovarian epithelial tumorigenesis: correlation between morphologi-cal and molecular data. Histol Histopathol 2006;21:81–92
- Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006;12:432–441